Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Aim(s): To monitor effects and side effects of the new tryptophan hydroxylase inhibitor telotristat in a population with late stage metastasized GI-NET disease with ongoing highdose SSA and often earlier Lutetium or interferon treatment.
Materials and methods: 16 patients in Karolinska Endocrine Tumor department were treated with telotristat in increasing doses from 250 mg to 750 mg daily. They had metastasized disease in liver, lymphnodes, or skeleton, G1(4) or G2(12) and high dU-5-HIAA or S-5-HIAA (4-18 times ULN). Most hade earlier received gut surgery, SSA (ongoing every second-third week injection) and Lutetium (8/12) or Sirtex(1) but progressed symptomatically, biochemically and radiologically.
Conference: 17th Annual ENETSConcerence (2020)
Authors: Linder Ekberg K,
To read the full abstract, please log into your ENETS Member account.